The JAK2 V617F mutation is found in patients with blood-related diseases such as polycythemia vera, essential thrombocythemia and myelofibrosis. Ruxolitinib is effective as a JAK inhibitor, making it a prognostic factor in determining drug response. Detection of the JAK2 V617F mutation facilitates the classification of patients with MPD (myeloproliferative disease) into three levels of diagnostic certainty (possible, probable and definitive) and to determine which signal transduction therapy is appropriate for each patient. In addition, the WHO (World Health Organization) has recommended JAK2 V617F mutation testing as a clinical trial.
PNAClamp™ Mutation Detection Kit JAK2
For the detection of JAK2 mutations in tissue biopsies
Cat. No. PNAC-6001
Other products
Biospin Plasmid DNA Extraction Kit-250T-PCR/RT-PCR KIT(BSC01L1)
Economical and simple kit for preparing plasmid DNA, ready for...
WATER ULTRA PURE 500 ML
ultrapure cell culture grade water free of DNases, RNases, proteases...
Logix Smart ABC
Logix Smart ABC (Influenza A/B,SARS-CoV-2) Co-Diagnostics Inc.
15 ml, 30 ml and 50 ml centrifuge tubes
The 15 ml and 50 ml conical centrifuge tubes are...